title: Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells.
abstract: Gene transfer into hCD34(+) hematopoietic stem/progenitor cells (HSCs) using human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors (LVs) has several promising therapeutic applications. Yet, efficiency, safety, and cost of LV gene therapy could be ameliorated by enhancing target cell transduction levels and reducing the amount of LV used on the cells. Several transduction enhancers already exist such as fibronectin fragments and cationic compounds, but all present limitations. In this study, we describe a new transduction enhancer called Vectofusin-1, which is a short cationic peptide, active on several LV pseudotypes. Vectofusin-1 is used as a soluble additive to safely increase the frequency of transduced HSCs and to augment the level of transduction to one or two copies of vector per cell in a vector dose-dependent manner. Vectofusin-1 acts at the entry step by promoting the adhesion and the fusion between viral and cellular membranes. Vectofusin-1 is therefore a promising additive that could significantly ameliorate hCD34(+) cell-based gene therapy.Molecular Therapy-Nucleic Acids (2013) 2, e90; doi:10.1038/mtna.2013.17; published online 7 May 2013.
authors: 1] Généthon, Evry, France [2] INSERM, UMR_S951, Généthon, Evry, France [3] Université Evry Val d'Essonne, UMR_S951, Evry, France.
authors: David
authors: D
authors: Fenard
authors: Dina
authors: D
authors: Ingrao
authors: Ababacar
authors: A
authors: Seye
authors: Julien
authors: J
authors: Buisset
authors: Sandrine
authors: S
authors: Genries
authors: Samia
authors: S
authors: Martin
authors: Antoine
authors: A
authors: Kichler
authors: Anne
authors: A
authors: Galy
references: J Gene Med. 2004 Feb;6 Suppl 1:S105-24
references: 14978755
references: Mol Ther. 2005 Mar;11(3):452-9
references: 15727942
references: Cell. 2007 Dec 14;131(6):1059-71
references: 18083097
references: Blood. 2008 Dec 15;112(13):4843-52
references: 18812471
references: Virology. 1969 Jul;38(3):414-26
references: 4308055
references: Biophys J. 2010 Oct 20;99(8):2507-15
references: 20959091
references: Methods Mol Biol. 2004;263:333-44
references: 14976375
references: Blood. 1996 Aug 1;88(3):855-62
references: 8704241
references: Mol Ther. 2000 Jul;2(1):71-80
references: 10899830
references: Pharm Res. 2010 Jul;27(7):1426-36
references: 20393870
references: PLoS Pathog. 2011 Jan 20;7(1):e1001260
references: 21283788
references: Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):545-50
references: 21971332
references: J Virol Methods. 1989 Feb;23(2):187-94
references: 2786000
references: Curr Opin Mol Ther. 2009 Oct;11(5):554-64
references: 19806504
references: Antimicrob Agents Chemother. 2006 Oct;50(10):3305-11
references: 17005809
references: Trends Biotechnol. 2008 May;26(5):267-75
references: 18358551
references: J Pept Sci. 2011 Feb;17(2):88-93
references: 21234979
references: Biophys J. 2004 Feb;86(2):1234-42
references: 14747357
references: Curr Gene Ther. 2005 Aug;5(4):387-98
references: 16101513
references: Retrovirology. 2009 Mar 02;6:20
references: 19254359
references: Cell. 2009 May 1;137(3):433-44
references: 19410541
references: Cell Stem Cell. 2009 Jul 2;5(1):17-26
references: 19570510
references: Gene Ther. 2011 May;18(5):479-87
references: 21160533
references: Hum Gene Ther. 2011 Mar;22(3):343-56
references: 21043787
references: Retrovirology. 2011 Dec 06;8:99
references: 22145853
references: J Gene Med. 2010 Feb;12(2):137-46
references: 20052742
references: Hum Gene Ther. 2001 Nov 20;12(17):2095-108
references: 11747599
references: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1564-8
references: 12563034
references: Gene Ther. 2013 Jan;20(1):16-23
references: 22218301
references: J Biol Chem. 2009 Jan 2;284(1):119-133
references: 18984589
references: Nat Methods. 2010 Nov;7(11):929-35
references: 20935652
references: Gene Ther. 2009 May;16(5):700-5
references: 19212424
references: Nat Biotechnol. 1996 Mar;14(3):339-42
references: 9630897
references: Blood. 2002 Aug 1;100(3):823-32
references: 12130492
references: FASEB J. 2006 Feb;20(2):320-2
references: 16352649
references: Cytotherapy. 2008;10(4):406-16
references: 18574773
references: Mol Ther. 2011 Apr;19(4):686-93
references: 21224833
references: Nat Rev Genet. 2011 May;12(5):301-15
references: 21445084
references: J Pept Sci. 2008 Apr;14(4):488-95
references: 18085719
references: J Virol. 1990 Feb;64(2):957-61
references: 2153257
references: Nat Med. 1996 Aug;2(8):876-82
references: 8705856
references: Methods Mol Biol. 2008;415:65-82
references: 18370148
references: Nat Biotechnol. 2002 Nov;20(11):1151-4
references: 12355096
references: Virology. 1967 Sep;33(1):175-7
references: 4292341
references: Mol Ther. 2008 Aug;16(8):1427-36
references: 18578012
references: J Virol. 2009 Jan;83(1):73-80
references: 18945786
references: Mol Ther. 2009 Jun;17(6):1083-92
references: 19277017
references: Nat Protoc. 2009;4(4):495-505
references: 19300443
references: Nat Med. 2003 Apr;9(4):367-9
references: 12669036
references: J Clin Invest. 1994 Apr;93(4):1451-7
references: 8163649